Guaifenesin and Pseudoephedrine HCL
NDC 55111-798, Guaifenesin and Pseudoephedrine HCL, tablet, extended release, from Dr. Reddys Laboratories Limited.
- Product NDC
- 55111-798
- Status
- Listed
- Labeler
- Dr. Reddys Laboratories Limited
- Dosage form
- TABLET, EXTENDED RELEASE
- Route
- ORAL
- Product type
- HUMAN OTC DRUG
- Marketing category
- ANDA
- Application
- ANDA208369
- DEA schedule
- None
curl https://api.healthcare.dev/v1/drugs/ndc/55111-798 \ -H "Authorization: Bearer $HDEV_API_KEY"
Product
Active ingredients and packages
Active ingredients
- GUAIFENESIN600 mg/1
- PSEUDOEPHEDRINE HYDROCHLORIDE60 mg/1
Pharmacologic classes
Adrenergic alpha-Agonists [MoA]; Decreased Respiratory Secretion Viscosity [PE]; Expectorant [EPC]; Increased Respiratory Secretions [PE]; alpha-Adrenergic Agonist [EPC]
| Package NDC | NDC-11 | Package |
|---|---|---|
| 55111-798-09 | 55111079809 | 1 BLISTER PACK in 1 CARTON (55111-798-09) / 9 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
| 55111-798-18 | 55111079818 | 2 BLISTER PACK in 1 CARTON (55111-798-18) / 9 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
| 55111-798-35 | 55111079835 | 1 BLISTER PACK in 1 CARTON (55111-798-35) / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
| 55111-798-36 | 55111079836 | 4 BLISTER PACK in 1 CARTON (55111-798-36) / 9 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
| 55111-798-41 | 55111079841 | 2 BLISTER PACK in 1 CARTON (55111-798-41) / 18 TABLET, EXTENDED RELEASE in 1 BLISTER PACK |
Linked data
RxNorm, label and prices
RxNorm concepts
Related lookups
NADAC price for package 55111079818
GET /v1/drugs/nadac/55111079818NADAC price for package 55111079835
GET /v1/drugs/nadac/55111079835NADAC price for package 55111079836
GET /v1/drugs/nadac/55111079836NADAC price for package 55111079841
GET /v1/drugs/nadac/55111079841
Use it
Look up 55111-798 from code or an agent
curl https://api.healthcare.dev/v1/drugs/ndc/55111-798 \ -H "Authorization: Bearer $HDEV_API_KEY"
Using the healthcare.dev MCP server, look up NDC 55111-798. Tell me the product, its labeler, dosage form and route, its packages, and the RxNorm concepts it maps to.
Source: FDA, release 2026-10-23. Public domain. Reference data, not medical advice.